CASP1 and Insulin resistance: AC-YVAD-CMK treatment markedly decreased caspase-1 activity (Fig. 5a), serum IL-1β (Fig. 5b), blood glucose (Fig. 5c), fasting serum insulin levels (Fig. 5d), and HOMA, an indicator of insulin resistance (Fig. 5e).